




stabilizers for said nanoparticles allowing targeting of said one or more physiologically effective substances to a specific site within or on a mammalian body, said one or more stabilizers being selected from the group consisting of polysorbate 85, polysorbate 81, dextran 12,000, carboxylic acid esters of glycerol, sorbitan monostearate, sorbitan monooleate, polyoxamer 188, polyoxarnines, alkoxyated ethers, alkoxyated esters, alkoxyated mono-, di and triglycerides, alkoxyated phenols and diphenols, Genapol® compounds, Bauki compounds^R, sodium stearate, metal salts of carboxylic acids, metal salts of alcohol sulfates and metal salts of sulfosuccinates and mixtures of two or more of said substances, wherein said Genapol^R compounds are of the formula



wherein y is in the range of 4 to 18 and x is in the range of 1 to 18,

and said Bauki^R compounds are of the formulas (I) or (I')



in which R₁, R₂, R₅ and R₆ are identical or different and represent hydrogen and a methyl or ethyl group,

Q represents a valency, oxygen or an ester or amide bridge and Q' denotes hydrogen if Q represents a valency or oxygen, and is a hydroxyl or amino group if Q represents an ester or amide bridge,

x is an integer from 3 to 50, if Q is a valency or oxygen, and an integer from 3 to 1000, if Q is an ester or amide function, G₁ and G₂ are a valency, oxygen or an ester or amide group, it being possible for the two groups to be identical or different, n is an integer from 4 to 44, y is an integer from 2 to 50, and R₃ is hydrogen or a lower alkyl having 1-6 C atoms, and; by polymerizing one or more monomeric or oligomeric precursors of said polymeric material or both, in the presence of said one or more physiologically effective substances and in the presence of said stabilizers; and optionally

b) providing said nanoparticles in a medium allowing the transport of said nanoparticles to a target within or on said mammal after administration.

REMARKS

Claim 101 has been amended in order to correct a typographical error and to make this claim consistent with the disclosure at page 16, lines 9-23, as amended by the amendment of May 29, 2002, line 6 of such amendment.